Background Phosphate binders are used to reduce positive phosphate balance and to lower
serum phosphate levels for people with chronic kidney disease (CKD) with the aim to …

Background Oral nicotinamide is recommended in individuals with a field of cancerization or
with≥ 1 previous cutaneous squamous cell carcinoma (cSCC). Objective To evaluate the …

Management of hyperphosphatemia in patients with dialysis-dependent chronic kidney
disease remains a major challenge, requiring a multifaceted approach that includes dietary …

Introduction Despite widespread use of phosphate binders (PBs), phosphate control is
insufficient in many hemodialysis patients. Preliminary clinical observations suggest that …

Background We previously reported that modified-release nicotinamide (NAMR) was
superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large …

Post-synthesis (de) hydration techniques were used here to explore further hydrated forms
of ionic co-crystals (ICCs) of nicotinamide with CaCl2. Humidity is shown to be a crucial …

Группа изобретений относится к области медицины, а именно к внутренним болезням,
и предназначена для предупреждения и/или лечения гиперфосфатемии и …

The present invention relates to a pharmaceutical preparation comprising modified release
nicotinamide, as well as its use in a method of preventing and/or treating of elevated serum …